Ambee Pharmaceuticals Statistics

Total Valuation

Ambee Pharmaceuticals has a market cap or net worth of BDT 1.73 billion. The enterprise value is 2.14 billion.

Market Cap	1.73B
Enterprise Value	2.14B

Important Dates

The last earnings date was Sunday, November 10, 2024.

Earnings Date	Nov 10, 2024
Ex-Dividend Date	Dec 3, 2024

Share Statistics

Ambee Pharmaceuticals has 2.40 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	2.40M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	68.30%
Owned by Institutions (%)	n/a
Float	760,730

Valuation Ratios

The trailing PE ratio is 162.07.

PE Ratio	162.07
Forward PE	n/a
PS Ratio	8.43
PB Ratio	70.51
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 99.37, with an EV/FCF ratio of -31.77.

EV / Earnings	200.57
EV / Sales	10.44
EV / EBITDA	99.37
EV / EBIT	162.52
EV / FCF	-31.77

Financial Position

The company has a current ratio of 0.90, with a Debt / Equity ratio of 18.14.

Current Ratio	0.90
Quick Ratio	0.35
Debt / Equity	18.14
Debt / EBITDA	20.66
Debt / FCF	-6.60
Interest Coverage	15.30

Financial Efficiency

Return on equity (ROE) is 30.43% and return on invested capital (ROIC) is 1.91%.

Return on Equity (ROE)	30.43%
Return on Assets (ROA)	1.56%
Return on Capital (ROIC)	1.91%
Revenue Per Employee	430,270
Profits Per Employee	22,392
Employee Count	477
Asset Turnover	0.39
Inventory Turnover	0.49

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.21% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-15.21%
50-Day Moving Average	851.94
200-Day Moving Average	795.73
Relative Strength Index (RSI)	32.55
Average Volume (20 Days)	4,057

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ambee Pharmaceuticals had revenue of BDT 205.24 million and earned 10.68 million in profits. Earnings per share was 4.45.

Revenue	205.24M
Gross Profit	109.70M
Operating Income	13.18M
Pretax Income	12.32M
Net Income	10.68M
EBITDA	21.40M
EBIT	13.18M
Earnings Per Share (EPS)	4.45

Full Income Statement

Balance Sheet

The company has 34.24 million in cash and 445.42 million in debt, giving a net cash position of -411.18 million or -171.33 per share.

Cash & Cash Equivalents	34.24M
Total Debt	445.42M
Net Cash	-411.18M
Net Cash Per Share	-171.33
Equity (Book Value)	24.55M
Book Value Per Share	10.23
Working Capital	-55.13M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -65.43 million and capital expenditures -2.01 million, giving a free cash flow of -67.44 million.

Operating Cash Flow	-65.43M
Capital Expenditures	-2.01M
Free Cash Flow	-67.44M
FCF Per Share	-28.10

Full Cash Flow Statement

Margins

Gross margin is 53.45%, with operating and profit margins of 6.42% and 5.20%.

Gross Margin	53.45%
Operating Margin	6.42%
Pretax Margin	6.00%
Profit Margin	5.20%
EBITDA Margin	10.43%
EBIT Margin	6.42%
FCF Margin	-32.86%

Dividends & Yields

This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.21%.

Dividend Per Share	1.50
Dividend Yield	0.21%
Dividend Growth (YoY)	50.00%
Years of Dividend Growth	1
Payout Ratio	29.77%
Buyback Yield	n/a
Shareholder Yield	0.21%
Earnings Yield	0.62%
FCF Yield	-3.90%

Dividend Details

Stock Splits

The last stock split was on May 29, 2014. It was a forward split with a ratio of 1.2.

Last Split Date	May 29, 2014
Split Type	Forward
Split Ratio	1.2

Scores

Ambee Pharmaceuticals has an Altman Z-Score of 2.25. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.25
Piotroski F-Score	n/a